摘要
原发性膜性肾病(IMN)是肾衰竭的主要原因之一,约52%的肾病综合征(NS)病例可归因于IMN,尤其是在40岁以上患者中,这一比例更是超过60%。深入探索膜性肾病(MN)的发病机制及有效治疗策略显得尤为重要。在IMN的治疗方面,主要治疗方法包括限制钠摄入、使用血管紧张素转换酶抑制剂(ACEI)或血管紧张素受体阻滞剂(ARB)、免疫抑制疗法。鉴于糖皮质激素、免疫抑制剂等传统药物疗效有限且存在一定不良反应,靶向治疗及分子生物疗法等已成为研究热点。该文对近年来关于IMN的支持治疗、传统药物治疗、免疫抑制疗法及新兴药物治疗的研究进展进行综述,以期为IMN患者的管理和治疗提供参考。
Idiopathic membranous nephropathy(IMN)is one of the main causes of renal failure.Approximately 52% of nephrotic syndrome(NS)cases can be attributed to IMN,with this proportion even exceeding 60% in patients over 40 years old.It is particularly important to explore the pathogenesis and effective treatment strategies of membranous nephropathy(MN).The main treatments for IMN include sodium restriction,angiotensin-converting enzyme inhibitors(ACEI)or angiotensin receptor blockers(ARB),and immunosuppressive therapy.Given the limited efficacy and adverse reactions of traditional drugs such as glucocorticoids and immunosuppressants,targeted therapy and molecular biological therapy have become research hotspots.This article reviews recent research progress in IMN treatments including supportive care,traditional drug therapy,immunosuppression therapy,and new drug therapy,to provide insights and directions for the management and treatment of IMN patients.
作者
张富玥
严瑞
ZHANG Fuyue;YAN Rui(Department of Nephrology,the Affiliated Hospital of Guizhou Medical University,Guiyang,Guizhou 550004,China)
出处
《重庆医学》
2025年第8期1930-1935,共6页
Chongqing Medical Journal
基金
贵州省科学技术基金项目(黔科合基础-ZK〔2021〕一般379号)。
关键词
原发性膜性肾病
支持治疗
糖皮质激素
免疫抑制
靶向治疗
idiopathic membranous nephropathy
supportive care
glucocorticoids
immunosuppression
targeted therapy
